7 news items
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target
CNTB
13 Jun 24
HC Wainwright & Co. analyst Emily Bodnar reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $8 price target.
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CNTB
12 Jun 24
targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
CNTB
12 Jun 24
molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
CNTB
22 May 24
functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
CNTB
7 May 24
and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201
0vj16is0gr5kuxoxxll3uko3auiz71yen08wjtztx 0x
CNTB
17 Apr 24
HC Wainwright & Co. analyst Emily Bodnar maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and raises the price target from $7 to $8.
wazqcqys71144kgb8mo r9eugsmdj7o0hguk2b
CNTB
16 Apr 24
), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001). J
- Prev
- 1
- Next